Merus (MRUS)
(Real Time Quote from BATS)
$47.96 USD
+0.94 (2.00%)
Updated May 2, 2024 11:32 AM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Merus N.V. [MRUS]
Reports for Purchase
Showing records 121 - 140 ( 173 total )
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
CD137 Bispecific Antibody Kills Tumors in Mice
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
NRG1 Fusion Focus for MCLA-128 Ultimately a Positive
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Refocusing Efforts in NRG1 Fusion - Positive Solid Tumors
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
SITC Is Only 33 Days Away: Abstract Titles Released
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Biotechnology - ESMO 2019 Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Elevating the Game with Multiple Escalation Studies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
2Q19 - T-Cell Engager Shows Early Signs of Activity
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Initiating at Buy with $20 PT.
Provider: Roth Capital Partners, Inc.
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
1Q19 Financials; Multiple Updates Coming in H2
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Biotechnology - AACR Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
4Q18 Financials; Early-Stage Biclonics Programs Hold Significant Promise
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
3Q18 Financials; Data-Rich 2H19 Expected for MCLA-128, 117 and 145
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D